Lifecare highlights real-world veterinary relevance from ongoing diabetes study

19 Jan 2026 07:00 CET

Bergen, Norway, 19 January 2026 - Lifecare ASA (LIFE) today shares early
real-world experience from its ongoing study LFC-SEN-002, illustrating how
continuous glucose insight in a veterinary setting can support improved
diabetes management and quality of life for dogs with diabetes.

The first diabetic dog in the study was enrolled in December 2025: a
12-year-old mixed-breed dog with a long history of diabetes, who has been
under specialist veterinary care since August 2025.

With close follow-up and strong veterinary expertise, adjustments were made to
the dog's diabetes management during the study period, contributing to
improved glucose control and overall well-being.

Lifecare's veterinary study is also designed to generate practical learning
for product development and future human clinical programs.

Real-life improvement in diabetes management

Following study enrolment, the dog has been closely monitored by veterinarians
at the Norwegian University of Life Sciences (NMBU). During the initial phase,
the veterinarians were able to optimise diabetes management based on enhanced
access to continuous glucose insight and close clinical follow-up. This
resulted in observable improvements in glucose regulation and overall
well-being.

The improvements are attributed to a clinician-led approach, combined with
frequent monitoring and a better understanding of glucose patterns over time,
supporting more informed treatment adjustments.

"Based on feedback from the veterinarians involved in the study, the
participating dog shows clear improvements in overall well-being and diabetes
management compared to earlier in the disease course," says Joacim Holter, CEO
of Lifecare. "This highlights the practical value of close monitoring and
continuous glucose insight in veterinary diabetes care."

Veterinary studies as a learning platform for development

Initial data from LFC-SEN-002 demonstrate the practical relevance of
continuous glucose insight in veterinary diabetes care.

Insights from long-term in-vivo operation, real-world glucose dynamics, and
system behaviour in a biological environment are informing further
optimisation of the implant and supporting preparation for future human
clinical programs.

"Veterinary medicine allows us to observe how continuous glucose insight
supports real clinical care within a clinician-led decision-making
framework," Holter adds. "These learnings are highly valuable for our product
development and help de-risk future human programs, while we remain
disciplined in the use of investigational devices."

Strengthening the veterinary pathway and human roadmap

Early experience from LFC-SEN-002 strengthens Lifecare's confidence in:

* the relevance of continuous glucose monitoring in veterinary diabetes care,
* the company's planned veterinary market pathway, and
* the role of veterinary studies as an important step in Lifecare's broader
development and regulatory strategy.

The study continues to generate data supporting both veterinary market
preparation and progress toward first-in-human studies and CE marking.

About LFC-SEN-002

LFC-SEN-002 is an ongoing longevity and performance study evaluating
Lifecare's implantable CGM technology in dogs. The study focuses on
biocompatibility, system stability, and in-vivo signal behaviour, and supports
both veterinary product development and future human clinical programs. The
study is conducted under veterinary supervision in cooperation with the
Faculty of Veterinary Medicine, Department of Companion Animal Clinical
Sciences at the Norwegian University of Life Sciences. Data generated in the
study provide direct input to Lifecare's ongoing development and execution
program.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

663796_Lifecare highlights real-world veterinary relevance from ongoing diabetes study.pdf